Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Concert Pharmaceuticals
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
Clinical lab results within the normal range
You may not be if
Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
Treatment with systemic immunosuppressive medications or biologics.
Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Clareo Health | Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
